Under Waxman’s microscope
Executive Summary
Public health consequences of drug-resistant microbes will be examined Nov. 7 by the House Oversight and Government Reform Committee. Reports about methicillin-resistant Staphylococcus aureus have focused public attention on the issue and may provide impetus for federal legislation. Sens. Sherrod Brown, D-Ohio, and Orrin Hatch, R-Utah, introduced Oct. 31 an antimicrobial resistance bill that already is pending in the House (1"The Pink Sheet" Oct. 15, 2007, p. 9). The proposed law would improve "our grasp on resistance and ways to control it," notes Donald Peretz, president of the Infectious Diseases Society of America. IDSA has been urging Congress for several years to create incentives for the development of new drugs to fight microorganisms resistant to existing therapies...
You may also be interested in...
Antimicrobial Drug Reviews Would Need To Consider “Resistance” Under Bill
Impact on drug-resistant microbes would be a factor considered during the review of antimicrobial drug applications under legislation introduced in the House Sept. 27 by Reps. Jim Matheson, D-Utah, and Mike Ferguson, R-N.J
China VBP, Localization And Other Strategies - How Far And Which Way?
Could health sector players encounter issues similar to those facing Tesla in China, a country which virtually saved the electric vehicle maker but where it is now facing challenges? Are there any lessons to be learned from a success story under China's volume-based procurement scheme? A partner at EY looks at these and other issues in an interview with Scrip.
Ratio Therapeutics On BMS Investment, Radiopharma R&D Trends, AI Use
The CEO and CSO of radiopharmaceutical company Ratio Therapeutics, which now has Bristol Myers Squibb as an investor, talk about Ratio’s R&D platforms, use of AI, an independent FAP-targeted asset and trends in radiopharma research such as combining other modalities like ADCs, in this podcast interview with Scrip